首页 > 最新文献

Medical Hypothesis, Discovery, and Innovation in Ophthalmology最新文献

英文 中文
Sutureless-dehydrated amniotic membrane (Omnigen®) mounted on contact lens (OmniLenz®) in the treatment of small corneal perforations secondary to exposure keratitis in ICU patients. 无缝合线脱水羊膜(Omnigen®)贴合隐形眼镜(OmniLenz®)治疗ICU患者暴露性角膜炎继发小角膜穿孔
Q2 Medicine Pub Date : 2025-12-17 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1532
Nancy M Lotfy, Mubarak Alrasheedi, Rola Y Khachaba, Hamad Alshatti, Yousef Taleb Ali
<p><strong>Background: </strong>Exposure keratopathy is a common ocular complication in patients admitted to the intensive care unit (ICU) and may progress from superficial epithelial breakdown to corneal perforation, a vision-threatening emergency requiring timely management. Conventional treatments often necessitate urgent surgery, which is challenging in critically ill individuals who are unsuitable for surgical intervention. OmniLenz®, a customized bandage contact lens pre-lined with vacuum-dried Omnigen® amniotic membrane, offers a practical, non-surgical, bedside alternative for managing small corneal perforations. This study evaluates its clinical outcomes in ICU patients with a small corneal perforation secondary to exposure keratitis.</p><p><strong>Methods: </strong>This prospective interventional case series included ICU patients with <1 mm corneal perforations secondary to exposure keratitis, recruited over a two-year interval. All patients underwent corneal scraping with culture and sensitivity testing, followed by targeted antimicrobial therapy. A dehydrated amniotic membrane (Omnigen®) was applied beneath a customized bandage contact lens (OmniLenz®) at the bedside under sterile conditions. Patients were examined daily using a portable slit-lamp and followed for one month. The primary outcome was perforation closure, defined by a negative Seidel test and anterior chamber reformation. Secondary outcomes included improvement in epithelial integrity, corneal infiltration, and ciliary injection.</p><p><strong>Results: </strong>Five ICU patients, aged 18 to 70 years, with < 1 mm corneal perforations secondary to exposure keratitis were included. All eyes demonstrated rapid tectonic recovery following Omnigen®/OmniLenz® device application. Anterior chamber reformation and a negative Seidel test were achieved by day 7 in four patients and by day 10 in one patient. Complete perforation closure occurred in all cases. Marked improvement in keratitis was observed, with full epithelial defect healing and resolution of corneal infiltrates in every patient, followed by stable grade-3 stromal scarring. No neovascularization, device-related adverse events, or treatment complications occurred during the one-month follow-up.</p><p><strong>Conclusions: </strong>Omnigen®/OmniLenz® device provides a safe, effective, and non-invasive bedside treatment for small corneal perforations secondary to exposure keratitis in critically ill ICU patients. Its use enabled consistent tectonic restoration, rapid perforation closure, and resolution of infection-associated corneal pathology without procedure-related complications. This approach offers a practical alternative to urgent surgical intervention in patients unsuitable for operative care and may serve as a valuable addition to corneal perforation management protocols. Further studies with larger cohorts are needed to evaluate its safety and efficacy in larger perforations and to determine long-term outcomes, i
背景:暴露性角膜病变是重症监护病房(ICU)患者常见的眼部并发症,可能从浅表上皮破裂发展为角膜穿孔,这是一种威胁视力的紧急情况,需要及时处理。常规治疗往往需要紧急手术,这对不适合手术干预的危重患者来说是具有挑战性的。OmniLenz®是一种定制的绷带隐形眼镜,预先内衬真空干燥的Omnigen®羊膜,为治疗小角膜穿孔提供了一种实用的、非手术的床边替代方案。本研究评估了暴露性角膜炎继发小角膜穿孔ICU患者的临床结果。结果:5例ICU患者,年龄18 ~ 70岁,继发于暴露性角膜炎的角膜穿孔< 1mm。Omnigen®/OmniLenz®设备应用后,所有人都看到了快速的构造恢复。4例患者在第7天和1例患者在第10天实现前房改革和塞德尔试验阴性。所有病例的穿孔均完全闭合。观察到角膜炎的明显改善,每个患者的上皮缺损完全愈合,角膜浸润消失,随后出现稳定的3级间质瘢痕。在一个月的随访期间,未发生新生血管、器械相关不良事件或治疗并发症。结论:Omnigen®/OmniLenz®设备为重症ICU患者暴露性角膜炎继发小角膜穿孔提供了一种安全、有效、无创的床边治疗方法。它的使用能够实现一致的构造修复,快速关闭穿孔,解决感染相关的角膜病理,而没有手术相关的并发症。该方法为不适合手术治疗的患者提供了紧急手术治疗的实用替代方法,并可作为角膜穿孔治疗方案的宝贵补充。进一步的研究需要更大的队列来评估其在较大穿孔中的安全性和有效性,并确定长期结果,包括角膜瘢痕和视力。
{"title":"Sutureless-dehydrated amniotic membrane (Omnigen®) mounted on contact lens (OmniLenz®) in the treatment of small corneal perforations secondary to exposure keratitis in ICU patients.","authors":"Nancy M Lotfy, Mubarak Alrasheedi, Rola Y Khachaba, Hamad Alshatti, Yousef Taleb Ali","doi":"10.51329/mehdiophthal1532","DOIUrl":"https://doi.org/10.51329/mehdiophthal1532","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Exposure keratopathy is a common ocular complication in patients admitted to the intensive care unit (ICU) and may progress from superficial epithelial breakdown to corneal perforation, a vision-threatening emergency requiring timely management. Conventional treatments often necessitate urgent surgery, which is challenging in critically ill individuals who are unsuitable for surgical intervention. OmniLenz®, a customized bandage contact lens pre-lined with vacuum-dried Omnigen® amniotic membrane, offers a practical, non-surgical, bedside alternative for managing small corneal perforations. This study evaluates its clinical outcomes in ICU patients with a small corneal perforation secondary to exposure keratitis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This prospective interventional case series included ICU patients with &lt;1 mm corneal perforations secondary to exposure keratitis, recruited over a two-year interval. All patients underwent corneal scraping with culture and sensitivity testing, followed by targeted antimicrobial therapy. A dehydrated amniotic membrane (Omnigen®) was applied beneath a customized bandage contact lens (OmniLenz®) at the bedside under sterile conditions. Patients were examined daily using a portable slit-lamp and followed for one month. The primary outcome was perforation closure, defined by a negative Seidel test and anterior chamber reformation. Secondary outcomes included improvement in epithelial integrity, corneal infiltration, and ciliary injection.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Five ICU patients, aged 18 to 70 years, with &lt; 1 mm corneal perforations secondary to exposure keratitis were included. All eyes demonstrated rapid tectonic recovery following Omnigen®/OmniLenz® device application. Anterior chamber reformation and a negative Seidel test were achieved by day 7 in four patients and by day 10 in one patient. Complete perforation closure occurred in all cases. Marked improvement in keratitis was observed, with full epithelial defect healing and resolution of corneal infiltrates in every patient, followed by stable grade-3 stromal scarring. No neovascularization, device-related adverse events, or treatment complications occurred during the one-month follow-up.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Omnigen®/OmniLenz® device provides a safe, effective, and non-invasive bedside treatment for small corneal perforations secondary to exposure keratitis in critically ill ICU patients. Its use enabled consistent tectonic restoration, rapid perforation closure, and resolution of infection-associated corneal pathology without procedure-related complications. This approach offers a practical alternative to urgent surgical intervention in patients unsuitable for operative care and may serve as a valuable addition to corneal perforation management protocols. Further studies with larger cohorts are needed to evaluate its safety and efficacy in larger perforations and to determine long-term outcomes, i","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 4","pages":"194-203"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12840571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the predictive value of optical coherence tomography angiography metrics and central corneal thickness among glaucoma suspect patients: a comparative cross-sectional study. 评估光学相干断层扫描血管造影指标和中央角膜厚度在青光眼疑似患者中的预测价值:一项比较横断面研究。
Q2 Medicine Pub Date : 2025-12-17 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1531
Fathy Mohamed Abo Elftouh Elsalhy, Sarah Abbas Alshamarti, Saif Abbas Alshamarti, Abdelrahman Ahmed Ali Khattab, Mahmoud Mohammed Ahmed Ali Khalil, Mahmoud Fawzy Zaky Morsy, Ahmad Mohammad Salah Eldeen Abdul Hay, Ezzat Nabil Abbas Ibrahim, Ahmed Mohammed Madinah Alkady, Mahmoud Ahmed Shafeek, Bassem Ismail Khalil Gomaa, Mohamed Sayed Taha Abouzeid

Background: Glaucoma suspects (GS) exhibit risk factors such as elevated intraocular pressure (IOP), suspicious optic disc or retinal nerve fiber layer (RNFL) findings, or a positive family history, yet their risk of progression varies widely. Optical coherence tomography angiography (OCTA) and central corneal thickness (CCT) have emerged as important markers for detecting early structural and microvascular changes in GS patients. We aimed to estimate the predictive value of OCTA-derived metrics and CCT, and to assess their correlations in GS individuals.

Methods: This comparative cross-sectional study included eyes from GS patients and eyes from age- and sex-matched healthy individuals as a comparison group. All participants underwent a detailed medical history and comprehensive ophthalmologic examination. Investigations included visual field perimetry; optical coherence tomography (OCT) to assess structural optic nerve head parameters, RNFL thickness, and ganglion cell layer (GCL) thickness; OCTA to measure papillary vascular density (PVD) and radial peripapillary capillary density (RPC); and non-contact specular microscopy to determine CCT.

Results: The GS group had a mean age of 36.9 years, with 52.4% male (n = 11). GS eyes showed significantly larger CDR values, reduced rim area, thinner RNFL and GCL, and lower CCT compared with healthy eyes (all P < 0.05). Mean RPC, quadrant-specific RPC values, and mean PVD were significantly reduced in GS individuals (all P < 0.05). CCT showed significant correlations with all vascular metrics and structural parameters (all P < 0.05), except disc area (P > 0.05). In univariate logistic regression all variables were associated with GS status. After multivariate adjustment, only CCT ≤ 506 µm remained an independent predictor. Receiver operating characteristic curve analysis showed good diagnostic performance for CCT (area under the curve [AUC] = 0.757) and mean RPC (AUC = 0.820) in identifying GS eyes.

Conclusions: Patients with GS revealed significantly lower structural parameters and vascular metrics compared with the healthy group, and only thin CCT remained an independent predictor of GS status. Both CCT and mean RPC demonstrated good diagnostic performance for identifying GS eyes.

背景:疑似青光眼(GS)表现出眼压升高、可疑视盘或视网膜神经纤维层(RNFL)发现或阳性家族史等危险因素,但其进展风险差异很大。光学相干断层血管造影(OCTA)和角膜中央厚度(CCT)已成为检测GS患者早期结构和微血管变化的重要标志。我们的目的是估计octa衍生指标和CCT的预测价值,并评估它们在GS个体中的相关性。方法:本比较横断面研究包括来自GS患者的眼睛和来自年龄和性别匹配的健康个体的眼睛作为对照组。所有参与者都接受了详细的病史和全面的眼科检查。调查包括视野测量;光学相干断层扫描(OCT)评估结构视神经头参数、RNFL厚度和神经节细胞层(GCL)厚度;OCTA测量乳头状血管密度(PVD)和径向乳头周围毛细血管密度(RPC);和非接触式镜面显微镜测定CCT。结果:GS组平均年龄36.9岁,男性占52.4% (n = 11)。与健康眼相比,GS眼CDR值显著增大,边缘面积减小,RNFL和GCL变薄,CCT降低(均P < 0.05)。GS个体的平均RPC、象限特异性RPC值和平均PVD均显著降低(均P < 0.05)。CCT与除椎间盘面积(P < 0.05)外的所有血管指标和结构参数均有显著相关性(P < 0.05)。在单变量逻辑回归中,所有变量都与GS状态相关。多因素调整后,只有CCT≤506µm仍然是独立的预测因子。受试者工作特征曲线分析显示CCT(曲线下面积[AUC] = 0.757)和平均RPC (AUC = 0.820)对GS眼有较好的诊断效果。结论:与健康组相比,GS患者的结构参数和血管指标明显降低,只有薄CCT仍然是GS状态的独立预测因子。CCT和平均RPC对GS眼均有较好的诊断效果。
{"title":"Evaluating the predictive value of optical coherence tomography angiography metrics and central corneal thickness among glaucoma suspect patients: a comparative cross-sectional study.","authors":"Fathy Mohamed Abo Elftouh Elsalhy, Sarah Abbas Alshamarti, Saif Abbas Alshamarti, Abdelrahman Ahmed Ali Khattab, Mahmoud Mohammed Ahmed Ali Khalil, Mahmoud Fawzy Zaky Morsy, Ahmad Mohammad Salah Eldeen Abdul Hay, Ezzat Nabil Abbas Ibrahim, Ahmed Mohammed Madinah Alkady, Mahmoud Ahmed Shafeek, Bassem Ismail Khalil Gomaa, Mohamed Sayed Taha Abouzeid","doi":"10.51329/mehdiophthal1531","DOIUrl":"https://doi.org/10.51329/mehdiophthal1531","url":null,"abstract":"<p><strong>Background: </strong>Glaucoma suspects (GS) exhibit risk factors such as elevated intraocular pressure (IOP), suspicious optic disc or retinal nerve fiber layer (RNFL) findings, or a positive family history, yet their risk of progression varies widely. Optical coherence tomography angiography (OCTA) and central corneal thickness (CCT) have emerged as important markers for detecting early structural and microvascular changes in GS patients. We aimed to estimate the predictive value of OCTA-derived metrics and CCT, and to assess their correlations in GS individuals.</p><p><strong>Methods: </strong>This comparative cross-sectional study included eyes from GS patients and eyes from age- and sex-matched healthy individuals as a comparison group. All participants underwent a detailed medical history and comprehensive ophthalmologic examination. Investigations included visual field perimetry; optical coherence tomography (OCT) to assess structural optic nerve head parameters, RNFL thickness, and ganglion cell layer (GCL) thickness; OCTA to measure papillary vascular density (PVD) and radial peripapillary capillary density (RPC); and non-contact specular microscopy to determine CCT.</p><p><strong>Results: </strong>The GS group had a mean age of 36.9 years, with 52.4% male (n = 11). GS eyes showed significantly larger CDR values, reduced rim area, thinner RNFL and GCL, and lower CCT compared with healthy eyes (all <i>P</i> < 0.05). Mean RPC, quadrant-specific RPC values, and mean PVD were significantly reduced in GS individuals (all <i>P</i> < 0.05). CCT showed significant correlations with all vascular metrics and structural parameters (all <i>P</i> < 0.05), except disc area (<i>P</i> > 0.05). In univariate logistic regression all variables were associated with GS status. After multivariate adjustment, only CCT ≤ 506 µm remained an independent predictor. Receiver operating characteristic curve analysis showed good diagnostic performance for CCT (area under the curve [AUC] = 0.757) and mean RPC (AUC = 0.820) in identifying GS eyes.</p><p><strong>Conclusions: </strong>Patients with GS revealed significantly lower structural parameters and vascular metrics compared with the healthy group, and only thin CCT remained an independent predictor of GS status. Both CCT and mean RPC demonstrated good diagnostic performance for identifying GS eyes.</p>","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 4","pages":"183-193"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12840569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crosslinking of tarsal collagen as a hypothetical therapy for dry eye disease. 跗骨胶原交联作为干眼病的假设疗法。
Q2 Medicine Pub Date : 2025-12-17 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1535
Alexandra I Manta, Shuko Suzuki, Traian V Chirila

Background: Dry eye disease (DED) is one of the most prevalent and distressing ocular conditions worldwide; it primarily results from alterations in the natural tear film that covers the ocular surface and is often due to enhanced evaporation of its aqueous component. This process is frequently associated with dysfunction of the meibomian glands (MGs), which are embedded within the tarsal plate of our eyelids and secrete the meibum, an oily mixture of proteins and lipids. Meibum forms the outermost layer of the tear film, playing a critical role in controlling water evaporation and stabilizing the tear film by lowering surface tension. Meibomian gland dysfunction (MGD) may result from structural abnormalities in the MGs, such as tortuosity, which impair normal delivery of meibum. Increased laxity of the eyelid is also associated with development of MGD and DED, likely due to insufficient mechanical support for the glands, and causing morphological changes.

Hypothesis: We designed and initiated the development of a noninvasive method to strengthen and stiffen the tarsal collagen containing the embedded MGs. By reducing tissue laxity, our aim is to halt further morphological deterioration of the glands and promote uniform and smooth delivery of meibum to the ocular surface. Our previous studies showed that both mechanical tensile strength and rigidity (Young's modulus) of tarsal collagen in animal and human eyelids were significantly enhanced by exposure to ultraviolet-A (UV-A) radiation with a wavelength of 365 nm in the presence of riboflavin as a photosensitizer.

Conclusions: We propose that performing this procedure at the initial manifestations of MGD and DED may prevent disease progression by restoring and preserving the normal morphology of the glands through reduced laxity, thereby ensuring proper secretion of the meibum into the tear film. The underlying principles and safety of the procedure were discussed in detail, and further pre-clinical evaluation steps were proposed and justified. Based on the proposed concept and the results of previous ex-vivo studies, in-vivo animal experiments and human clinical trials are currently in preparation.

背景:干眼病(DED)是世界范围内最常见和最令人痛苦的眼部疾病之一;它主要是由于覆盖眼表的天然泪膜的改变,通常是由于其含水成分的蒸发增强。这一过程通常与睑板腺功能障碍有关,睑板腺位于眼睑的跗骨板内,分泌睑板,一种由蛋白质和脂质组成的油性混合物。Meibum形成了泪膜的最外层,通过降低表面张力,在控制水分蒸发和稳定泪膜方面起着关键作用。睑板腺功能障碍(MGD)可能是由睑板腺结构异常引起的,如扭曲,损害睑板腺的正常输送。眼睑松弛的增加也与MGD和DED的发展有关,可能是由于腺体的机械支持不足,并引起形态学改变。假设:我们设计并开发了一种非侵入性方法来加强和硬化含有嵌入mg的跗骨胶原。通过减少组织松弛,我们的目标是阻止腺体进一步的形态恶化,促进均匀和顺利地将睑脂输送到眼表。我们之前的研究表明,在核黄素作为光敏剂存在的情况下,动物和人类眼睑的跗骨胶原蛋白的机械拉伸强度和刚度(杨氏模量)在365 nm波长的紫外线a (UV-A)辐射下均显著增强。结论:我们认为,在MGD和DED的最初表现时进行这种手术可以通过减少松弛来恢复和保持腺体的正常形态,从而确保细胞脂分泌到泪膜中,从而预防疾病的进展。详细讨论了该程序的基本原则和安全性,并提出并证明了进一步的临床前评估步骤。基于提出的概念和以往离体研究的结果,体内动物实验和人体临床试验目前正在准备中。
{"title":"Crosslinking of tarsal collagen as a hypothetical therapy for dry eye disease.","authors":"Alexandra I Manta, Shuko Suzuki, Traian V Chirila","doi":"10.51329/mehdiophthal1535","DOIUrl":"https://doi.org/10.51329/mehdiophthal1535","url":null,"abstract":"<p><strong>Background: </strong>Dry eye disease (DED) is one of the most prevalent and distressing ocular conditions worldwide; it primarily results from alterations in the natural tear film that covers the ocular surface and is often due to enhanced evaporation of its aqueous component. This process is frequently associated with dysfunction of the meibomian glands (MGs), which are embedded within the tarsal plate of our eyelids and secrete the meibum, an oily mixture of proteins and lipids. Meibum forms the outermost layer of the tear film, playing a critical role in controlling water evaporation and stabilizing the tear film by lowering surface tension. Meibomian gland dysfunction (MGD) may result from structural abnormalities in the MGs, such as tortuosity, which impair normal delivery of meibum. Increased laxity of the eyelid is also associated with development of MGD and DED, likely due to insufficient mechanical support for the glands, and causing morphological changes.</p><p><strong>Hypothesis: </strong>We designed and initiated the development of a noninvasive method to strengthen and stiffen the tarsal collagen containing the embedded MGs. By reducing tissue laxity, our aim is to halt further morphological deterioration of the glands and promote uniform and smooth delivery of meibum to the ocular surface. Our previous studies showed that both mechanical tensile strength and rigidity (Young's modulus) of tarsal collagen in animal and human eyelids were significantly enhanced by exposure to ultraviolet-A (UV-A) radiation with a wavelength of 365 nm in the presence of riboflavin as a photosensitizer.</p><p><strong>Conclusions: </strong>We propose that performing this procedure at the initial manifestations of MGD and DED may prevent disease progression by restoring and preserving the normal morphology of the glands through reduced laxity, thereby ensuring proper secretion of the meibum into the tear film. The underlying principles and safety of the procedure were discussed in detail, and further pre-clinical evaluation steps were proposed and justified. Based on the proposed concept and the results of previous ex-vivo studies, in-vivo animal experiments and human clinical trials are currently in preparation.</p>","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 4","pages":"233-250"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12840572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of reactive oxygen species and oxidative stress in the pathomechanism of glaucoma. 活性氧和氧化应激在青光眼发病机制中的作用。
Q2 Medicine Pub Date : 2025-12-17 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1533
Nicholas T H Chan, Ushasree Pattamatta, Andrew White

Background: Glaucoma is a major cause of vision impairment and blindness, characterized by damage to retinal ganglion cells (RGC) at the optic nerve head (ONH). The pathomechanism underlying glaucoma is heterogeneous and theories explaining the pathomechanism can be categorized as mechanical, vascular, or immunological. This mini-review explores the involvement of reactive oxygen species (ROS) and oxidative stress in these established mechanisms of glaucoma.

Methods: A review of literature was conducted using PubMed/MEDLINE, with the query including the following keywords: "antioxidants", "glaucoma", "glaucoma pathomechanism", "immunological", "intraocular pressure", "mechanical", "reactive oxygen species", "ocular hypertension", "oxidative stress", and "vascular". The date filter was set from January 2010 to September 2025. Papers that were relevant to ROS or oxidative stress in the glaucoma pathomechanism were thoroughly reviewed. Their reference lists were also reviewed for relevant papers of any date.

Results: Following a comprehensive literature search, 67 journal articles were selected for review. They revealed the role of ROS and oxidative stress in the mechanical, vascular, and immunological pathomechanism theories of glaucoma. In the mechanical theory, oxidative stress mediates RGC apoptosis and trabecular meshwork damage. In vascular processes, retinal ischemia causes oxidative stress and vice versa, thus causing RGC death and ONH damage. With the immunological theory, ROS is implicated in glial cell and inflammasome activity that causes RGC injury. Key players in the generation of oxidative stress include NADP oxidase 2, dynamin-related protein 1, mitofusin 2, nuclear factor (erythroid-derived 2)‑like 2, and nitric oxide. Conversely, various antioxidant factors are also implicated in glaucoma, yet in oxidative stress conditions their effects are outweighed by those of ROS.

Conclusions: ROS and oxidative stress are important mediators in the glaucoma pathomechanism. They contribute to and unify the existing theories of mechanical, vascular, and immunological injury in glaucoma. Investigating specific oxidative stress players in the pathomechanism may reveal new therapeutic targets in the treatment of glaucoma.

背景:青光眼是视力障碍和失明的主要原因,其特征是视神经头(ONH)的视网膜神经节细胞(RGC)受损。青光眼的发病机制是多种多样的,解释其发病机制的理论可分为机械性、血管性和免疫学。这篇综述探讨了活性氧(ROS)和氧化应激在这些已建立的青光眼机制中的作用。方法:通过PubMed/MEDLINE检索相关文献,查询关键词:“抗氧化剂”、“青光眼”、“青光眼发病机制”、“免疫学”、“眼压”、“机械性”、“活性氧”、“高眼压”、“氧化应激”、“血管”。日期过滤器设置为从2010年1月到2025年9月。本文对活性氧或氧化应激在青光眼发病机制中的相关研究进行了综述。还审查了他们的参考书目,以查找任何日期的相关论文。结果:经过全面的文献检索,我们选择了67篇期刊文章进行综述。他们揭示了ROS和氧化应激在青光眼的机械、血管和免疫病理机制理论中的作用。在力学理论中,氧化应激介导RGC细胞凋亡和小梁网损伤。在血管过程中,视网膜缺血引起氧化应激,反之亦然,从而引起RGC死亡和ONH损伤。根据免疫学理论,ROS与胶质细胞和炎性体活动有关,导致RGC损伤。氧化应激产生的关键参与者包括NADP氧化酶2、动力蛋白相关蛋白1、丝裂酶2、核因子(红细胞衍生的2)样2和一氧化氮。相反,各种抗氧化因子也与青光眼有关,但在氧化应激条件下,它们的作用被活性氧的作用所抵消。结论:活性氧和氧化应激在青光眼的发病机制中起重要的调节作用。它们有助于并统一现有的青光眼的机械、血管和免疫损伤理论。研究氧化应激在青光眼发病机制中的特殊作用,可能为青光眼的治疗提供新的治疗靶点。
{"title":"Role of reactive oxygen species and oxidative stress in the pathomechanism of glaucoma.","authors":"Nicholas T H Chan, Ushasree Pattamatta, Andrew White","doi":"10.51329/mehdiophthal1533","DOIUrl":"https://doi.org/10.51329/mehdiophthal1533","url":null,"abstract":"<p><strong>Background: </strong>Glaucoma is a major cause of vision impairment and blindness, characterized by damage to retinal ganglion cells (RGC) at the optic nerve head (ONH). The pathomechanism underlying glaucoma is heterogeneous and theories explaining the pathomechanism can be categorized as mechanical, vascular, or immunological. This mini-review explores the involvement of reactive oxygen species (ROS) and oxidative stress in these established mechanisms of glaucoma.</p><p><strong>Methods: </strong>A review of literature was conducted using PubMed/MEDLINE, with the query including the following keywords: \"antioxidants\", \"glaucoma\", \"glaucoma pathomechanism\", \"immunological\", \"intraocular pressure\", \"mechanical\", \"reactive oxygen species\", \"ocular hypertension\", \"oxidative stress\", and \"vascular\". The date filter was set from January 2010 to September 2025. Papers that were relevant to ROS or oxidative stress in the glaucoma pathomechanism were thoroughly reviewed. Their reference lists were also reviewed for relevant papers of any date.</p><p><strong>Results: </strong>Following a comprehensive literature search, 67 journal articles were selected for review. They revealed the role of ROS and oxidative stress in the mechanical, vascular, and immunological pathomechanism theories of glaucoma. In the mechanical theory, oxidative stress mediates RGC apoptosis and trabecular meshwork damage. In vascular processes, retinal ischemia causes oxidative stress and vice versa, thus causing RGC death and ONH damage. With the immunological theory, ROS is implicated in glial cell and inflammasome activity that causes RGC injury. Key players in the generation of oxidative stress include NADP oxidase 2, dynamin-related protein 1, mitofusin 2, nuclear factor (erythroid-derived 2)‑like 2, and nitric oxide. Conversely, various antioxidant factors are also implicated in glaucoma, yet in oxidative stress conditions their effects are outweighed by those of ROS.</p><p><strong>Conclusions: </strong>ROS and oxidative stress are important mediators in the glaucoma pathomechanism. They contribute to and unify the existing theories of mechanical, vascular, and immunological injury in glaucoma. Investigating specific oxidative stress players in the pathomechanism may reveal new therapeutic targets in the treatment of glaucoma.</p>","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 4","pages":"204-215"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12840570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visual outcomes for the initial 500 eyes treated with keratorefractive lenticule extraction (KLEx) for myopia and myopic astigmatism at a single-site. 单点角膜屈光性晶状体摘除(KLEx)治疗近视和近视散光500只眼的视力结果
Q2 Medicine Pub Date : 2025-12-17 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1530
Bryce L Palmer, Mina M Sitto, Jonathan C Davis, Phillip C Hoopes, Majid Moshirfar

Background: Keratorefractive lenticule extraction (KLEx) has become a widely used corneal refractive surgery. Since its approval by the United States Food and Drug Administration (FDA), there are relatively few studies from large US cohorts that have evaluated visual outcomes beyond one year using KLEx for myopia and myopic astigmatism. Studies are often limited by their small sample size and short follow-up duration.

Methods: This was a retrospective study of 577 eyes from 314 patients who underwent KLEx between March 2017 and May 2024 at a single refractive surgery center. Inclusion criteria were myopia between 9.25 and 1.00 D, cylinder up to 3.00 D, and preoperative corrected distance visual acuity (CDVA) of 20/20 or better. Uncorrected distance visual acuity (UDVA), CDVA, manifest refraction, and complications were evaluated at 3 and 12 months postoperatively. Clinical outcomes were also compared to FDA premarket trials and large international cohorts.

Results: Of 577 treated eyes, data were available at 3 months for 511 eyes (88.6% follow-up) and 12 months for 440 eyes (76.3% follow-up). Mean spherical equivalent (SEQ) improved from 5.35 ± 1.62 D ( 9.63 to 1.38 D) to 0.04 ± 0.44 D ( 1.88 to 1.88 D) (P < 0.001). Mean cylinder improved from 0.66 ± 0.66 D ( 3.00 to 0.00 D) at baseline to 0.40 ± 0.32 D ( 1.75 to 0.00 D) at 12 months (P < 0.001). Additionally, postoperative UDVA was 20/20 or better in 81% of eyes and 20/25 or better in 94% of eyes. Postoperative SEQ was within ± 0.50 D in 85% of eyes and within ± 1.00 D in 97% of eyes at 12 months. The SEQ remained stable across all postoperative visits, with a mean change of 0.03 ± 0.38 D from 3 to 12 months. There was a gain of one line of CDVA in 16% of eyes at 12 months, with no eyes losing two or more CDVA lines. Target-induced and surgically induced astigmatism were strongly correlated at both 3 and 12 months, with a mean undercorrection of 20% by one year (R² = 0.69).

Conclusions: KLEx demonstrates predictable and safe correction of myopia and myopic astigmatism over 12 months in a US cohort. Visual outcomes meet or exceed FDA benchmarks and are consistent with published literature, although a potential need for improved cylindrical correction remains.

背景:角膜屈光性晶状体摘除术(KLEx)已成为一种应用广泛的角膜屈光手术。自KLEx获得美国食品和药物管理局(FDA)批准以来,来自美国大型队列的评估使用KLEx治疗近视和近视散光超过一年的视力结果的研究相对较少。研究往往受到样本量小和随访时间短的限制。方法:回顾性研究了2017年3月至2024年5月在单一屈光手术中心接受KLEx手术的314例患者的577只眼睛。纳入标准为近视度数9.25 ~ 1.00 D,眼柱面度数3.00 D,术前矫正距离视力(CDVA)在20/20及以上。术后3个月和12个月评估未矫正距离视力(UDVA)、CDVA、明显屈光及并发症。临床结果也与FDA上市前试验和大型国际队列进行了比较。结果:在577只治疗眼中,511只眼(88.6%随访)和440只眼(76.3%随访)在3个月时可获得数据。平均球当量(SEQ)由5.35±1.62 D (9.63 ~ 1.38 D)改善至0.04±0.44 D (1.88 ~ 1.88 D) (P < 0.001)。12个月时,平均柱面由基线时的0.66±0.66 D (3.00 ~ 0.00 D)改善至0.40±0.32 D (1.75 ~ 0.00 D) (P < 0.001)。此外,81%的眼睛术后UDVA为20/20或更好,94%的眼睛为20/25或更好。术后12个月,85%的眼睛SEQ在±0.50 D内,97%的眼睛SEQ在±1.00 D内。SEQ在所有术后随访中保持稳定,从3到12个月的平均变化为0.03±0.38 D。12个月时,16%的眼睛有一条CDVA线增加,没有眼睛失去两条或两条以上的CDVA线。靶诱导散光和手术诱导散光在3个月和12个月时密切相关,平均1年的欠校正率为20% (R²= 0.69)。结论:在美国的一项研究中,KLEx在12个月内对近视和近视散光进行了可预测和安全的矫正。视觉结果达到或超过FDA的标准,并与已发表的文献一致,尽管仍有可能需要改进圆柱形矫正。
{"title":"Visual outcomes for the initial 500 eyes treated with keratorefractive lenticule extraction (KLEx) for myopia and myopic astigmatism at a single-site.","authors":"Bryce L Palmer, Mina M Sitto, Jonathan C Davis, Phillip C Hoopes, Majid Moshirfar","doi":"10.51329/mehdiophthal1530","DOIUrl":"https://doi.org/10.51329/mehdiophthal1530","url":null,"abstract":"<p><strong>Background: </strong>Keratorefractive lenticule extraction (KLEx) has become a widely used corneal refractive surgery. Since its approval by the United States Food and Drug Administration (FDA), there are relatively few studies from large US cohorts that have evaluated visual outcomes beyond one year using KLEx for myopia and myopic astigmatism. Studies are often limited by their small sample size and short follow-up duration.</p><p><strong>Methods: </strong>This was a retrospective study of 577 eyes from 314 patients who underwent KLEx between March 2017 and May 2024 at a single refractive surgery center. Inclusion criteria were myopia between 9.25 and 1.00 D, cylinder up to 3.00 D, and preoperative corrected distance visual acuity (CDVA) of 20/20 or better. Uncorrected distance visual acuity (UDVA), CDVA, manifest refraction, and complications were evaluated at 3 and 12 months postoperatively. Clinical outcomes were also compared to FDA premarket trials and large international cohorts.</p><p><strong>Results: </strong>Of 577 treated eyes, data were available at 3 months for 511 eyes (88.6% follow-up) and 12 months for 440 eyes (76.3% follow-up). Mean spherical equivalent (SEQ) improved from 5.35 ± 1.62 D ( 9.63 to 1.38 D) to 0.04 ± 0.44 D ( 1.88 to 1.88 D) (<i>P</i> < 0.001). Mean cylinder improved from 0.66 ± 0.66 D ( 3.00 to 0.00 D) at baseline to 0.40 ± 0.32 D ( 1.75 to 0.00 D) at 12 months (<i>P</i> < 0.001). Additionally, postoperative UDVA was 20/20 or better in 81% of eyes and 20/25 or better in 94% of eyes. Postoperative SEQ was within ± 0.50 D in 85% of eyes and within ± 1.00 D in 97% of eyes at 12 months. The SEQ remained stable across all postoperative visits, with a mean change of 0.03 ± 0.38 D from 3 to 12 months. There was a gain of one line of CDVA in 16% of eyes at 12 months, with no eyes losing two or more CDVA lines. Target-induced and surgically induced astigmatism were strongly correlated at both 3 and 12 months, with a mean undercorrection of 20% by one year (R² = 0.69).</p><p><strong>Conclusions: </strong>KLEx demonstrates predictable and safe correction of myopia and myopic astigmatism over 12 months in a US cohort. Visual outcomes meet or exceed FDA benchmarks and are consistent with published literature, although a potential need for improved cylindrical correction remains.</p>","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 4","pages":"171-182"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12840574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Canonical and noncanonical NF-κB signaling in uveal melanoma: mechanisms, microenvironment, and therapeutic modulation. 葡萄膜黑色素瘤中的典型和非典型NF-κB信号:机制、微环境和治疗调节。
Q2 Medicine Pub Date : 2025-12-17 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1534
Sobhan Jalali, Iman Dianat, Sina Baghi Keshtan, Reza Izadfar, Hamid Reza Esfandiari, Gholamhosein Lohrasbi, Faezeh Firuzpour

Background: Uveal melanoma (UM) is an aggressive intraocular malignancy with high metastatic potential to the liver and poor prognosis. The nuclear factor kappa B (NF-κB) pathway, comprising the canonical and noncanonical branches, has been involved in UM development, tumor-microenvironment communication, and drug resistance. This review consolidates the evidence for NF-κB involvement in UM pathogenesis and therapeutic target value.

Methods: A comprehensive search of PubMed/MEDLINE, Embase, Web of Science, Scopus, and the Cochrane CENTRAL database was performed from inception to June 2025. Studies investigating NF-κB activation, functional dependencies, genetic or microenvironmental modulators, or therapeutic interventions in UM were eligible. Included designs comprised original observational or experimental research, including mechanistic in vitro studies, animal models, and human tissue-based prognostic or correlative studies. English-language articles and relevant review studies addressing the research question were considered. Exclusion criteria included editorials, commentaries, conference abstracts with insufficient data, case reports lacking mechanistic insights, non-UM cancers without validated UM models, studies mentioning inflammation or NF-κB targets without direct NF-κB readouts, and those using pleiotropic inhibitors without genetic validation or pathway-specific evidence. Appropriate design-specific tools were applied to assess risk of bias.

Results: Canonical NF-κB signaling is mechanistically related to UM cell survival, proliferation, and migration, as shown by pharmacologic inhibition like BAY11-7082, and niclosamide and genetic modulation like microRNA-9. Noncanonical signaling is associated with invasive, immune-replenished tumors and liver metastasis yet has limited direct functional data. Deficiency in BRCA1-associated protein-1 (BAP1) and tumor necrosis factor alpha-enriched microenvironments control NF-κB activity, but there is conflicting data on the function of BAP1. Therapeutic targeting of NF-κB consistently suppresses UM phenotypes in vitro and in vivo, but pleiotropic inhibitor effects require confirmation.

Conclusions: NF-κB signaling, particularly the canonical branch, is required for UM malignancy, while noncanonical signaling is linked with high-risk features. Branch-specific genetic manipulations and clinically relevant models should be employed in future research to maximize therapeutic strategies.

背景:葡萄膜黑色素瘤(Uveal melanoma, UM)是一种侵袭性眼内恶性肿瘤,具有向肝脏转移的高潜力,预后差。核因子κB (NF-κB)通路包括典型和非典型分支,参与了UM的发展、肿瘤微环境通讯和耐药性。本文综述了NF-κB参与UM发病机制和治疗靶标价值的证据。方法:综合检索PubMed/MEDLINE、Embase、Web of Science、Scopus和Cochrane CENTRAL数据库,检索时间自成立至2025年6月。研究NF-κB激活、功能依赖性、遗传或微环境调节剂或UM治疗干预均符合条件。纳入的设计包括原始的观察性或实验性研究,包括体外机制研究、动物模型和基于人体组织的预后或相关研究。考虑了针对研究问题的英文文章和相关综述研究。排除标准包括数据不足的社论、评论、会议摘要、缺乏机制见解的病例报告、没有经过验证的UM模型的非UM癌症、提到炎症或NF-κB靶点但没有直接NF-κB数据的研究,以及使用没有遗传验证或通路特异性证据的多效抑制剂的研究。应用适当的设计专用工具来评估偏倚风险。结果:典型NF-κB信号通路与UM细胞存活、增殖和迁移的机制相关,如BAY11-7082的药理学抑制作用,以及尼科罗胺和microRNA-9的遗传调节作用。非典型信号与侵袭性、免疫补充肿瘤和肝转移有关,但直接功能数据有限。brca1相关蛋白-1 (BAP1)和肿瘤坏死因子α富集微环境的缺乏控制NF-κB活性,但BAP1的功能数据相互矛盾。在体外和体内,NF-κB的治疗靶点一致地抑制UM表型,但多效抑制剂的作用有待证实。结论:NF-κB信号,尤其是典型分支,是UM恶性肿瘤所必需的,而非典型信号则与高危特征有关。未来的研究应采用分支特异性基因操作和临床相关模型,以最大限度地提高治疗策略。
{"title":"Canonical and noncanonical NF-κB signaling in uveal melanoma: mechanisms, microenvironment, and therapeutic modulation.","authors":"Sobhan Jalali, Iman Dianat, Sina Baghi Keshtan, Reza Izadfar, Hamid Reza Esfandiari, Gholamhosein Lohrasbi, Faezeh Firuzpour","doi":"10.51329/mehdiophthal1534","DOIUrl":"https://doi.org/10.51329/mehdiophthal1534","url":null,"abstract":"<p><strong>Background: </strong>Uveal melanoma (UM) is an aggressive intraocular malignancy with high metastatic potential to the liver and poor prognosis. The nuclear factor kappa B (NF-κB) pathway, comprising the canonical and noncanonical branches, has been involved in UM development, tumor-microenvironment communication, and drug resistance. This review consolidates the evidence for NF-κB involvement in UM pathogenesis and therapeutic target value.</p><p><strong>Methods: </strong>A comprehensive search of PubMed/MEDLINE, Embase, Web of Science, Scopus, and the Cochrane CENTRAL database was performed from inception to June 2025. Studies investigating NF-κB activation, functional dependencies, genetic or microenvironmental modulators, or therapeutic interventions in UM were eligible. Included designs comprised original observational or experimental research, including mechanistic <i>in vitro</i> studies, animal models, and human tissue-based prognostic or correlative studies. English-language articles and relevant review studies addressing the research question were considered. Exclusion criteria included editorials, commentaries, conference abstracts with insufficient data, case reports lacking mechanistic insights, non-UM cancers without validated UM models, studies mentioning inflammation or NF-κB targets without direct NF-κB readouts, and those using pleiotropic inhibitors without genetic validation or pathway-specific evidence. Appropriate design-specific tools were applied to assess risk of bias.</p><p><strong>Results: </strong>Canonical NF-κB signaling is mechanistically related to UM cell survival, proliferation, and migration, as shown by pharmacologic inhibition like BAY11-7082, and niclosamide and genetic modulation like microRNA-9. Noncanonical signaling is associated with invasive, immune-replenished tumors and liver metastasis yet has limited direct functional data. Deficiency in BRCA1-associated protein-1 (BAP1) and tumor necrosis factor alpha-enriched microenvironments control NF-κB activity, but there is conflicting data on the function of BAP1. Therapeutic targeting of NF-κB consistently suppresses UM phenotypes <i>in vitro</i> and <i>in vivo</i>, but pleiotropic inhibitor effects require confirmation.</p><p><strong>Conclusions: </strong>NF-κB signaling, particularly the canonical branch, is required for UM malignancy, while noncanonical signaling is linked with high-risk features. Branch-specific genetic manipulations and clinically relevant models should be employed in future research to maximize therapeutic strategies.</p>","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 4","pages":"216-232"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12840573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical anatomy: cornea and ocular surface. 临床解剖:角膜和眼表。
Q2 Medicine Pub Date : 2025-09-27 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1524
Ozlem Ozkan, Canan Asli Utine
<p><strong>Background: </strong>The cornea and ocular surface serve as a vital barrier and the eye's primary refractive medium, requiring precise coordination to maintain transparency, structural integrity, and immune protection. Constantly exposed to environmental stressors, this interface relies on the stability of the tear film, epithelial architecture, mucin layers, and limbal stem cells to preserve function. Disruption in any component can impair vision and increase vulnerability to disease. Advances in imaging and molecular diagnostics have deepened our understanding of these structures, offering new avenues for early detection and personalized treatment strategies. A comprehensive review is needed to integrate recent findings and assess their clinical relevance.</p><p><strong>Methods: </strong>A targeted literature search was conducted using PubMed/MEDLINE and Google Scholar to identify English-language publications from 1 January 2000 to 30 May 2025. Keywords included "anatomy," "histology," "cornea," "ocular surface," "epithelium," "Bowman's layer," "stroma," "Descemet's membrane," "endothelium," "conjunctiva," "lacrimal functional unit," and "eyelids." Studies were selected irrespective of design, and reference lists of included articles were manually screened for additional relevant sources.</p><p><strong>Results: </strong>Eighty-six publications were reviewed. Findings highlight that the cornea and ocular surface constitute an integrated anatomical and physiological continuum essential for optical clarity, visual acuity, and ocular health. This dynamic unit comprises the cornea, conjunctiva, tear film (mucin, aqueous, and lipid layers), meibomian glands, goblet cells, and the limbal stem cell niche. Collectively, these elements provide lubrication, immune defense, epithelial homeostasis, and structural integrity. Disruption in any component-such as in dry eye disease, limbal stem cell deficiency, or meibomian gland dysfunction-can precipitate epithelial breakdown, neovascularization, or stromal scarring, ultimately compromising vision. Recognizing this interdependence has reframed ocular surface disease as a multifactorial condition rather than an isolated disorder. A comprehensive understanding of the structural and immunological dynamics of this system is therefore critical for refining surgical strategies and developing targeted therapies.</p><p><strong>Conclusions: </strong>The cornea and ocular surface components function synergistically to maintain a transparent, stable refractive surface essential for vision. Their coordinated roles in protection, lubrication, immune defense, and tissue repair reveal the importance of anatomical understanding for developing targeted therapies and improving clinical outcomes. A comprehensive understanding of this anatomy is essential for clinicians and researchers aiming to develop more precise therapeutic strategies and surgical techniques to enhance patient outcomes and preserve visual functio
背景:角膜和眼表是一个重要的屏障和眼睛的主要屈光介质,需要精确的协调来保持透明度、结构完整性和免疫保护。持续暴露于环境压力下,该界面依赖于泪膜、上皮结构、粘蛋白层和角膜缘干细胞的稳定性来保持功能。任何部分的破坏都会损害视力,增加对疾病的易感性。成像和分子诊断的进步加深了我们对这些结构的理解,为早期发现和个性化治疗策略提供了新的途径。需要一个全面的审查,以整合最近的发现和评估其临床相关性。方法:使用PubMed/MEDLINE和谷歌Scholar进行针对性文献检索,确定2000年1月1日至2025年5月30日的英文出版物。关键词包括“解剖学”、“组织学”、“角膜”、“眼表”、“上皮”、“鲍曼层”、“间质”、“Descemet膜”、“内皮”、“结膜”、“泪功能单位”和“眼睑”。无论设计如何,都选择了研究,并且人工筛选了纳入文章的参考文献列表以获取其他相关来源。结果:共回顾86篇文献。研究结果强调,角膜和眼表构成了一个完整的解剖和生理连续体,对光学清晰度、视力和眼部健康至关重要。这个动态单元包括角膜、结膜、泪膜(粘蛋白层、水层和脂层)、睑板腺、杯状细胞和角膜缘干细胞生态位。这些元素共同提供润滑、免疫防御、上皮稳态和结构完整性。任何成分的破坏,如干眼病、角膜缘干细胞缺乏或睑板腺功能障碍,都可能导致上皮破坏、新生血管形成或基质瘢痕形成,最终损害视力。认识到这种相互依存关系,将眼表疾病重新定义为一种多因素疾病,而不是一种孤立的疾病。因此,全面了解该系统的结构和免疫动力学对于改进手术策略和开发靶向治疗至关重要。结论:角膜和眼表成分协同作用,维持视力必需的透明、稳定的屈光面。它们在保护、润滑、免疫防御和组织修复中的协调作用揭示了解剖学对开发靶向治疗和改善临床结果的重要性。全面了解这种解剖结构对于临床医生和研究人员开发更精确的治疗策略和手术技术以提高患者预后和保持视觉功能至关重要。未来的研究应侧重于推进再生策略和个性化治疗,以更有效地解决复杂的眼表疾病。
{"title":"Clinical anatomy: cornea and ocular surface.","authors":"Ozlem Ozkan, Canan Asli Utine","doi":"10.51329/mehdiophthal1524","DOIUrl":"10.51329/mehdiophthal1524","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The cornea and ocular surface serve as a vital barrier and the eye's primary refractive medium, requiring precise coordination to maintain transparency, structural integrity, and immune protection. Constantly exposed to environmental stressors, this interface relies on the stability of the tear film, epithelial architecture, mucin layers, and limbal stem cells to preserve function. Disruption in any component can impair vision and increase vulnerability to disease. Advances in imaging and molecular diagnostics have deepened our understanding of these structures, offering new avenues for early detection and personalized treatment strategies. A comprehensive review is needed to integrate recent findings and assess their clinical relevance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A targeted literature search was conducted using PubMed/MEDLINE and Google Scholar to identify English-language publications from 1 January 2000 to 30 May 2025. Keywords included \"anatomy,\" \"histology,\" \"cornea,\" \"ocular surface,\" \"epithelium,\" \"Bowman's layer,\" \"stroma,\" \"Descemet's membrane,\" \"endothelium,\" \"conjunctiva,\" \"lacrimal functional unit,\" and \"eyelids.\" Studies were selected irrespective of design, and reference lists of included articles were manually screened for additional relevant sources.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Eighty-six publications were reviewed. Findings highlight that the cornea and ocular surface constitute an integrated anatomical and physiological continuum essential for optical clarity, visual acuity, and ocular health. This dynamic unit comprises the cornea, conjunctiva, tear film (mucin, aqueous, and lipid layers), meibomian glands, goblet cells, and the limbal stem cell niche. Collectively, these elements provide lubrication, immune defense, epithelial homeostasis, and structural integrity. Disruption in any component-such as in dry eye disease, limbal stem cell deficiency, or meibomian gland dysfunction-can precipitate epithelial breakdown, neovascularization, or stromal scarring, ultimately compromising vision. Recognizing this interdependence has reframed ocular surface disease as a multifactorial condition rather than an isolated disorder. A comprehensive understanding of the structural and immunological dynamics of this system is therefore critical for refining surgical strategies and developing targeted therapies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The cornea and ocular surface components function synergistically to maintain a transparent, stable refractive surface essential for vision. Their coordinated roles in protection, lubrication, immune defense, and tissue repair reveal the importance of anatomical understanding for developing targeted therapies and improving clinical outcomes. A comprehensive understanding of this anatomy is essential for clinicians and researchers aiming to develop more precise therapeutic strategies and surgical techniques to enhance patient outcomes and preserve visual functio","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 3","pages":"60-72"},"PeriodicalIF":0.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12528774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145330017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acanthamoeba keratitis: from pathophysiology to prevention, a contemporary clinical perspective. 棘阿米巴角膜炎:从病理生理到预防,当代临床视角。
Q2 Medicine Pub Date : 2025-09-27 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1528
Pelin Kiyat, Melis Palamar

Background: Acanthamoeba keratitis represents a devastating corneal infection caused by free-living protozoan organisms. This condition has evolved from an extraordinarily rare disease to a significant public health concern, with increasing global incidence. The infection predominantly affects contact lens wearers and poses substantial diagnostic and therapeutic challenges. This narrative review aims to provide analysis of current knowledge regarding Acanthamoeba keratitis, including epidemiology, pathogenesis, diagnostic approaches, treatment strategies, and prevention methods, to guide clinicians in optimal patient management.

Methods: This review was conducted through a literature search of PubMed-indexed journals from January 2000 to August 2025, incorporating current information on pathophysiology, clinical features, diagnosis, therapy, and outcomes of Acanthamoeba keratitis. Keywords included "Acanthamoeba keratitis", "contact lens-related keratitis", "Acanthamoeba diagnosis", and "Acanthamoeba treatment". English-language publications including original articles, reviews, case reports, and clinical studies were included based on relevance to current diagnostic and therapeutic practices, with an emphasis on recent advances in the field.

Results: Contact lens wearers comprised the vast majority of cases, with soft contact lens users representing the predominant affected population. Peak occurrence involves young adults aged 20-40 years, with water-based transmission through contaminated domestic supplies representing a significant risk pathway. Clinical manifestations commonly include epithelial abnormalities, stromal infiltration, and ring infiltrates in advanced cases. Traditional culture methods evidence limited sensitivity (33-67%), while advanced diagnostic approaches include polymerase chain reaction (PCR) and in vivo confocal microscopy (IVCM) achieving superior accuracy (sensitivity 77-100%, specificity 84-100%). First-line therapy employs biguanides and diamidines with prolonged administration. Advanced treatment options include oral miltefosine for refractory cases, azole antifungals, and surgical interventions ranging from epithelial debridement to corneal transplantation. Early diagnostic recognition represents the strongest predictor of visual recovery, with diagnostic delays associated with poor prognosis.

Conclusions: Acanthamoeba keratitis management requires high clinical suspicion, rapid diagnosis using advanced techniques such as IVCM and PCR, and prolonged antimicrobial therapy. Early diagnosis remains the most important predictor of visual recovery. Prevention through proper contact lens hygiene and water exposure avoidance is paramount. Future research priorities include development of novel antimicrobial agents and enhanced prevention strategies.

背景:棘阿米巴角膜炎是一种由自由生活的原生动物引起的破坏性角膜感染。这种情况已经从一种极其罕见的疾病演变为一种重大的公共卫生问题,全球发病率不断上升。这种感染主要影响隐形眼镜佩戴者,给诊断和治疗带来了巨大挑战。本文旨在分析棘阿米巴角膜炎的流行病学、发病机制、诊断方法、治疗策略和预防方法,以指导临床医生优化患者管理。方法:本综述通过检索2000年1月至2025年8月pubmed索引期刊的文献进行,纳入棘阿米巴角膜炎的病理生理学、临床特征、诊断、治疗和结局的最新信息。关键词:棘阿米巴角膜炎、隐形眼镜相关性角膜炎、棘阿米巴诊断、棘阿米巴治疗。包括原创文章、评论、病例报告和临床研究在内的英文出版物都是基于与当前诊断和治疗实践的相关性,重点是该领域的最新进展。结果:隐形眼镜佩戴者占绝大多数病例,软性隐形眼镜使用者占主要影响人群。发病率高峰发生在20-40岁的年轻人中,通过受污染的家庭供水的水基传播是一个重要的风险途径。临床表现通常包括上皮异常、间质浸润和晚期环状浸润。传统的培养方法灵敏度有限(33-67%),而先进的诊断方法包括聚合酶链反应(PCR)和体内共聚焦显微镜(IVCM),准确性更高(灵敏度77-100%,特异性84-100%)。一线治疗采用双胍类药物和二胺类药物,并延长给药时间。高级治疗方案包括难治性病例的口服米替福辛,抗真菌药物,以及从上皮清创到角膜移植的手术干预。早期诊断识别是视力恢复的最强预测因子,诊断延迟与预后不良相关。结论:棘阿米巴角膜炎的治疗需要临床高度怀疑,快速诊断,采用IVCM和PCR等先进技术,并长期抗菌治疗。早期诊断仍然是视力恢复最重要的预测指标。通过适当的隐形眼镜卫生和避免接触水来预防是至关重要的。未来的研究重点包括开发新型抗菌药物和加强预防策略。
{"title":"Acanthamoeba keratitis: from pathophysiology to prevention, a contemporary clinical perspective.","authors":"Pelin Kiyat, Melis Palamar","doi":"10.51329/mehdiophthal1528","DOIUrl":"10.51329/mehdiophthal1528","url":null,"abstract":"<p><strong>Background: </strong>Acanthamoeba keratitis represents a devastating corneal infection caused by free-living protozoan organisms. This condition has evolved from an extraordinarily rare disease to a significant public health concern, with increasing global incidence. The infection predominantly affects contact lens wearers and poses substantial diagnostic and therapeutic challenges. This narrative review aims to provide analysis of current knowledge regarding Acanthamoeba keratitis, including epidemiology, pathogenesis, diagnostic approaches, treatment strategies, and prevention methods, to guide clinicians in optimal patient management.</p><p><strong>Methods: </strong>This review was conducted through a literature search of PubMed-indexed journals from January 2000 to August 2025, incorporating current information on pathophysiology, clinical features, diagnosis, therapy, and outcomes of Acanthamoeba keratitis. Keywords included \"Acanthamoeba keratitis\", \"contact lens-related keratitis\", \"Acanthamoeba diagnosis\", and \"Acanthamoeba treatment\". English-language publications including original articles, reviews, case reports, and clinical studies were included based on relevance to current diagnostic and therapeutic practices, with an emphasis on recent advances in the field.</p><p><strong>Results: </strong>Contact lens wearers comprised the vast majority of cases, with soft contact lens users representing the predominant affected population. Peak occurrence involves young adults aged 20-40 years, with water-based transmission through contaminated domestic supplies representing a significant risk pathway. Clinical manifestations commonly include epithelial abnormalities, stromal infiltration, and ring infiltrates in advanced cases. Traditional culture methods evidence limited sensitivity (33-67%), while advanced diagnostic approaches include polymerase chain reaction (PCR) and in vivo confocal microscopy (IVCM) achieving superior accuracy (sensitivity 77-100%, specificity 84-100%). First-line therapy employs biguanides and diamidines with prolonged administration. Advanced treatment options include oral miltefosine for refractory cases, azole antifungals, and surgical interventions ranging from epithelial debridement to corneal transplantation. Early diagnostic recognition represents the strongest predictor of visual recovery, with diagnostic delays associated with poor prognosis.</p><p><strong>Conclusions: </strong>Acanthamoeba keratitis management requires high clinical suspicion, rapid diagnosis using advanced techniques such as IVCM and PCR, and prolonged antimicrobial therapy. Early diagnosis remains the most important predictor of visual recovery. Prevention through proper contact lens hygiene and water exposure avoidance is paramount. Future research priorities include development of novel antimicrobial agents and enhanced prevention strategies<b>.</b></p>","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 3","pages":"146-162"},"PeriodicalIF":0.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12528773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145330289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scleral lenses and PROSE: indications, complications, and future challenges. 巩膜晶状体和PROSE:适应证、并发症和未来挑战。
Q2 Medicine Pub Date : 2025-09-27 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1525
Alejandro Rodriguez-Garcia, Julio C Jimenez-Perez, Raul E Ruiz-Lozano, Andres Bustamante-Arias, Raul Hernan Barcelo-Canton

Background: Scleral lenses (SLs) and prosthetic replacement of the ocular surface environment (PROSE) are the same device, designed to enhance the optical quality of irregular surfaces or ectatic corneas. They also improve the corneal surface epithelium and the ocular surface microenvironment for patients with severe ocular surface diseases, including dry eye. This review aims to provide a comprehensive overview of the indications for SL/PROSE, as well as an exhaustive analysis of the corresponding complications, their possible remedies, and future challenges in this rapidly evolving field of ophthalmology.

Methods: We conducted a review of the English language literature on the indications and complications of SL/PROSE devices using the following website search engines: National Library of Medicine's PubMed, Google Scholar, EMBASE, Web of Science, and Scopus for articles in English published from inception up to July 2025. The following scientific reports were considered for analysis: systematic reviews and meta-analyses, randomized controlled trials, cohort studies, case-control series, case reports, editorials, and short communications.

Results: Research and development in SL/PROSE have made significant strides, broadening its applications, improving structural materials and designs, and adapting it to benefit a diverse range of patients facing numerous pathologies. These include keratoconus, post-refractive surgery ectasia, corneal transplantation, severe dry eye, and chronic cicatrizing ocular surface disorders, among many others. For patients suffering from these emerging pathologies, apart from medical therapy and surgical procedures there are limited treatment options. Currently, SL/PROSE offer a less invasive potential solution for many of these challenging conditions, raising hope and motivation within the field of corneal and ocular surface disease. However, they are not without potential complications, which differ significantly from those associated with soft contact lenses and rigid gas-permeable contact lenses. The most frequently reported SL/PROSE complications relate to improper lens adaptation and patients' handling.

Conclusions: While much of the existing literature has focused on the benefits and applications of SL/PROSE devices, the potential complications associated with their use have received less attention and aren't as widely explored.

背景:巩膜透镜(SLs)与眼表环境假体置换(PROSE)是同一种设备,旨在提高不规则表面或外翻角膜的光学质量。对于干眼症等严重眼表疾病患者,它们还能改善角膜表面上皮和眼表微环境。本综述旨在全面概述SL/PROSE的适应症,并详尽分析在这一快速发展的眼科领域中相应的并发症、可能的治疗方法和未来的挑战。方法:我们使用以下网站搜索引擎对SL/PROSE设备的适应症和并发症的英文文献进行了回顾:国家医学图书馆PubMed,谷歌Scholar, EMBASE, Web of Science和Scopus,检索从成立到2025年7月发表的英文文章。以下科学报告被纳入分析:系统评价和荟萃分析、随机对照试验、队列研究、病例对照系列、病例报告、社论和简短通讯。结果:SL/PROSE的研究和发展取得了重大进展,拓宽了其应用范围,改进了结构材料和设计,并使其适应于面临多种病理的各种患者。这些疾病包括圆锥角膜、屈光手术后扩张、角膜移植、严重干眼和慢性瘢痕性眼表疾病等。对于患有这些新出现的病症的患者,除了药物治疗和外科手术外,治疗选择有限。目前,SL/PROSE为许多这些具有挑战性的疾病提供了一种侵入性较小的潜在解决方案,为角膜和眼表疾病领域带来了希望和动力。然而,它们并非没有潜在的并发症,这与软性隐形眼镜和硬性透气性隐形眼镜有很大的不同。最常见的SL/PROSE并发症与晶状体适应不当和患者处理不当有关。结论:虽然现有的许多文献都集中在SL/PROSE设备的好处和应用上,但与使用SL/PROSE设备相关的潜在并发症却很少受到关注,也没有得到广泛的探讨。
{"title":"Scleral lenses and PROSE: indications, complications, and future challenges.","authors":"Alejandro Rodriguez-Garcia, Julio C Jimenez-Perez, Raul E Ruiz-Lozano, Andres Bustamante-Arias, Raul Hernan Barcelo-Canton","doi":"10.51329/mehdiophthal1525","DOIUrl":"10.51329/mehdiophthal1525","url":null,"abstract":"<p><strong>Background: </strong>Scleral lenses (SLs) and prosthetic replacement of the ocular surface environment (PROSE) are the same device, designed to enhance the optical quality of irregular surfaces or ectatic corneas. They also improve the corneal surface epithelium and the ocular surface microenvironment for patients with severe ocular surface diseases, including dry eye. This review aims to provide a comprehensive overview of the indications for SL/PROSE, as well as an exhaustive analysis of the corresponding complications, their possible remedies, and future challenges in this rapidly evolving field of ophthalmology.</p><p><strong>Methods: </strong>We conducted a review of the English language literature on the indications and complications of SL/PROSE devices using the following website search engines: National Library of Medicine's PubMed, Google Scholar, EMBASE, Web of Science, and Scopus for articles in English published from inception up to July 2025. The following scientific reports were considered for analysis: systematic reviews and meta-analyses, randomized controlled trials, cohort studies, case-control series, case reports, editorials, and short communications.</p><p><strong>Results: </strong>Research and development in SL/PROSE have made significant strides, broadening its applications, improving structural materials and designs, and adapting it to benefit a diverse range of patients facing numerous pathologies. These include keratoconus, post-refractive surgery ectasia, corneal transplantation, severe dry eye, and chronic cicatrizing ocular surface disorders, among many others. For patients suffering from these emerging pathologies, apart from medical therapy and surgical procedures there are limited treatment options. Currently, SL/PROSE offer a less invasive potential solution for many of these challenging conditions, raising hope and motivation within the field of corneal and ocular surface disease. However, they are not without potential complications, which differ significantly from those associated with soft contact lenses and rigid gas-permeable contact lenses. The most frequently reported SL/PROSE complications relate to improper lens adaptation and patients' handling.</p><p><strong>Conclusions: </strong>While much of the existing literature has focused on the benefits and applications of SL/PROSE devices, the potential complications associated with their use have received less attention and aren't as widely explored.</p>","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 3","pages":"73-106"},"PeriodicalIF":0.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12528766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145330015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-vascular endothelial growth factor therapies in ophthalmology. 抗血管内皮生长因子在眼科中的应用。
Q2 Medicine Pub Date : 2025-09-27 eCollection Date: 2025-01-01 DOI: 10.51329/mehdiophthal1526
Seher Koksaldi, Omer Karti, Ali Osman Saatci
<p><strong>Background: </strong>Retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, are leading causes of vision loss worldwide. The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies has dramatically changed the management of these conditions, offering targeted treatment that can preserve and even improve vision. We aimed to provide a comprehensive review of the development, clinical applications, and emerging indications of anti-VEGF therapies in ophthalmology, including biosimilar agents.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed/MEDLINE for English-language articles published up to 31 July 2025. Additional sources were identified through manual screening of reference lists. Included studies spanned various designs: clinical trials, meta-analyses, observational studies, and preclinical research. Keywords used in the search strategy included terms such as "anti-VEGF therapy", "biosimilar pharmaceuticals", "intravitreal and intrastromal anti-VEGF injections", "retinal diseases" including "macular degeneration" and "retinal neovascularization", "ranibizumab", and "bevacizumab", as well as relevant MeSH terms where applicable.</p><p><strong>Results: </strong>Anti-VEGF agents have transformed the management of retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema, proliferative diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity. Newer agents such as brolucizumab and faricimab offer prolonged durability and enhanced anatomic outcomes, while biosimilars provide cost-effective alternatives. Anti-VEGF therapy has also shown promise in off-label or emerging indications such as neovascular glaucoma, corneal neovascularization, and other retinal or choroidal disorders including secondary macular edema and/or macular neovascularization associated with various forms of uveitis, diffuse choroidal hemangioma in Sturge-Weber Syndrome, hereditary retinal disorders such as fundus flavimaculatus, Coats-Like retinitis pigmentosa, Peripherin-2-associated retinopathy, immune checkpoint inhibitor use, radiation retinopathy, retinitis pigmentosa, Bietti crystalline dystrophy, autosomal recessive bestrophinopathy, melanocytoma-associated macular neovascular membrane, Best disease, Wyburn-Mason syndrome, choroidal osteoma, peripheral exudative hemorrhagic chorioretinopathy, traumatic choroidal rupture, torpedo maculopathy, optic disc melanocytoma, type 2 proliferative macular telangiectasia, and Coats disease. High-dose formulations and innovative delivery systems are under active investigation to reduce the treatment burden and extend dosing intervals.</p><p><strong>Conclusions: </strong>Anti-VEGF therapies have revolutionized the field of ophthalmology, providing sight-saving treatment for a range of retinal diseases that were once considered untreatable or i
背景:视网膜疾病,包括新生血管性年龄相关性黄斑变性、糖尿病性视网膜病变和视网膜静脉阻塞,是世界范围内视力丧失的主要原因。抗血管内皮生长因子(anti-VEGF)疗法的引入极大地改变了这些疾病的治疗,提供了可以保护甚至改善视力的靶向治疗。我们旨在全面回顾眼科抗vegf疗法的发展、临床应用和新出现的适应症,包括生物类似药。方法:在PubMed/MEDLINE中检索到2025年7月31日之前发表的英文文章。通过手工筛选参考清单确定了其他来源。纳入的研究涵盖了各种设计:临床试验、荟萃分析、观察性研究和临床前研究。搜索策略中使用的关键词包括“抗vegf治疗”、“生物仿制药”、“玻璃体内和基质内抗vegf注射”、“视网膜疾病”(包括“黄斑变性”和“视网膜新生血管”)、“雷尼单抗”和“贝伐单抗”等术语,以及相关MeSH术语(如适用)。结果:抗vegf药物已经改变了视网膜疾病的治疗,如新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿、增殖性糖尿病视网膜病变、视网膜静脉闭塞和早产儿视网膜病变。较新的药物如brolucizumab和faricimab提供了更长的耐久性和更好的解剖结果,而生物仿制药提供了具有成本效益的替代品。抗vegf治疗在标签外或新出现的适应症中也显示出希望,如新生血管性青光眼、角膜新生血管和其他视网膜或脉络膜疾病,包括继发性黄斑水肿和/或与各种形式的葡萄膜炎相关的黄斑新生血管、斯特奇-韦伯综合征的弥漫性脉络膜血管瘤、遗传性视网膜疾病,如黄斑眼底、涂层样视网膜色素变性、周蛋白-2相关视网膜病变、免疫检查站抑制剂的使用、放射性视网膜病变、视网膜色素变性、Bietti晶体营养不良、常染色体隐性视网膜病变、黑素细胞瘤相关黄斑新生血管膜、Best病、Wyburn-Mason综合征、脉络膜骨瘤、外周渗出出血性脉络膜视网膜病变、外伤性脉络膜破裂、鱼雷黄斑病变、视盘黑素细胞瘤、2型增殖性黄斑毛细血管扩张和Coats病。正在积极研究高剂量配方和创新给药系统,以减轻治疗负担并延长给药间隔。结论:抗vegf疗法已经彻底改变了眼科领域,为一系列曾经被认为无法治疗或不可避免致盲的视网膜疾病提供了视力保护治疗。如今,抗vegf药物是治疗新生血管性视网膜疾病的首选药物,这要归功于它们已被证实的疗效、良好的安全性以及对现代眼科护理的革命性影响。
{"title":"Anti-vascular endothelial growth factor therapies in ophthalmology.","authors":"Seher Koksaldi, Omer Karti, Ali Osman Saatci","doi":"10.51329/mehdiophthal1526","DOIUrl":"10.51329/mehdiophthal1526","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, are leading causes of vision loss worldwide. The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies has dramatically changed the management of these conditions, offering targeted treatment that can preserve and even improve vision. We aimed to provide a comprehensive review of the development, clinical applications, and emerging indications of anti-VEGF therapies in ophthalmology, including biosimilar agents.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A comprehensive literature search was conducted in PubMed/MEDLINE for English-language articles published up to 31 July 2025. Additional sources were identified through manual screening of reference lists. Included studies spanned various designs: clinical trials, meta-analyses, observational studies, and preclinical research. Keywords used in the search strategy included terms such as \"anti-VEGF therapy\", \"biosimilar pharmaceuticals\", \"intravitreal and intrastromal anti-VEGF injections\", \"retinal diseases\" including \"macular degeneration\" and \"retinal neovascularization\", \"ranibizumab\", and \"bevacizumab\", as well as relevant MeSH terms where applicable.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Anti-VEGF agents have transformed the management of retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema, proliferative diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity. Newer agents such as brolucizumab and faricimab offer prolonged durability and enhanced anatomic outcomes, while biosimilars provide cost-effective alternatives. Anti-VEGF therapy has also shown promise in off-label or emerging indications such as neovascular glaucoma, corneal neovascularization, and other retinal or choroidal disorders including secondary macular edema and/or macular neovascularization associated with various forms of uveitis, diffuse choroidal hemangioma in Sturge-Weber Syndrome, hereditary retinal disorders such as fundus flavimaculatus, Coats-Like retinitis pigmentosa, Peripherin-2-associated retinopathy, immune checkpoint inhibitor use, radiation retinopathy, retinitis pigmentosa, Bietti crystalline dystrophy, autosomal recessive bestrophinopathy, melanocytoma-associated macular neovascular membrane, Best disease, Wyburn-Mason syndrome, choroidal osteoma, peripheral exudative hemorrhagic chorioretinopathy, traumatic choroidal rupture, torpedo maculopathy, optic disc melanocytoma, type 2 proliferative macular telangiectasia, and Coats disease. High-dose formulations and innovative delivery systems are under active investigation to reduce the treatment burden and extend dosing intervals.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Anti-VEGF therapies have revolutionized the field of ophthalmology, providing sight-saving treatment for a range of retinal diseases that were once considered untreatable or i","PeriodicalId":36524,"journal":{"name":"Medical Hypothesis, Discovery, and Innovation in Ophthalmology","volume":"14 3","pages":"107-135"},"PeriodicalIF":0.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12528764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145330328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Hypothesis, Discovery, and Innovation in Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1